Spinal Muscular Atrophy Patient Registry of the United Kingdom and Ireland

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Spinal muscular atrophy (SMA) is a form of motor neuron disease, most commonly caused by a mutation in the survival motor neuron 1 gene (SMN1) which results in a wide disease spectrum affecting children and adults. It is an autosomal recessive disorder and is therefore caused by inheritance of a mutated gene from each parent. All forms of SMA have an estimated combined incidence of 1 in 6,000 to 1 in 10,000 live births, with a carrier frequency of 1/40 to 1/60. The patient registry aims to facilitate a questionnaire-based research study in order to better characterise and understand the disease in the UK and in Ireland. Entry is via self-registration over a secure internet connection (https://www.sma-registry.org.uk/). Online, patients are asked to read an information sheet about the research project and then indicate their consent to demonstrate willingness to participate. Following online consent, subjects will be entered into the registry. This is an on-going database and all participants are invited to update their information on a biannual basis.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• All patients with a confirmed SMA diagnosis (or pending diagnosis) are eligible for inclusion. Diagnosis will be confirmed via genetic testing results

Locations
Other Locations
United Kingdom
John Walton Muscular Dystrophy Research Centre
RECRUITING
Newcastle Upon Tyne
Contact Information
Primary
Patient Registry manager and curator
smaregistry@newcastle.ac.uk
0191 2418640
Backup
Chiara Patient Registry Team
registries@newcastle.ac.uk
Time Frame
Start Date: 2008-07-13
Estimated Completion Date: 2025-05-31
Participants
Target number of participants: 800
Treatments
Participants with Spinal Muscular Atrophy
Sponsors
Collaborators: Adult SMA REACH, Roche Pharma AG, SMA REACH UK, Biogen
Leads: Newcastle University

This content was sourced from clinicaltrials.gov